-
1
-
-
33748952489
-
MEGA study group: MEGA study group primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial
-
Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y; MEGA Study Group: MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006; 368: 1155-1163.
-
(2006)
Lancet
, vol.368
, pp. 1155-1163
-
-
Nakamura, H.1
Arakawa, K.2
Itakura, H.3
Kitabatake, A.4
Goto, Y.5
Toyota, T.6
Nakaya, N.7
Nishimoto, S.8
Muranaka, M.9
Yamamoto, A.10
Mizuno, K.11
Ohashi, Y.12
-
2
-
-
0037031061
-
MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo- controlled trial
-
Heart Protection Study Collaborative Group
-
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo- controlled trial. Lancet, 2002; 360: 7-22
-
(2002)
Lancet
, vol.360
, pp. 7-22
-
-
-
3
-
-
33746895436
-
Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators: High-dose atorvastatin after stroke or transient ischemic attack
-
Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 2006; 355: 549-559
-
(2006)
N Engl J Med
, vol.355
, pp. 549-559
-
-
Amarenco, P.1
Bogousslavsky, J.2
Callahan III, A.3
Goldstein, L.B.4
Hennerici, M.5
Rudolph, A.E.6
Sillesen, H.7
Simunovic, L.8
Szarek, M.9
Welch, K.M.10
Zivin, J.A.11
-
5
-
-
0037420492
-
ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
-
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158
-
(2003)
Lancet
, vol.361
, pp. 1149-1158
-
-
Sever, P.S.1
Dahlöf, B.2
Poulter, N.R.3
Wedel, H.4
Beevers, G.5
Caulfield, M.6
Collins, R.7
Kjeldsen, S.E.8
Kristinsson, A.9
McInnes, G.T.10
Mehlsen, J.11
Nieminen, M.12
O'Brien, E.13
Ostergren, J.14
-
6
-
-
1542345696
-
Heart protection study collaborative group: Effects of cholesterol- lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions
-
Collins R, Armitage J, Parish S, Sleight P, Peto R. Heart Protection Study Collaborative Group: Effects of cholesterol- lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet, 2004; 363: 757-767
-
(2004)
Lancet
, vol.363
, pp. 757-767
-
-
Collins, R.1
Armitage, J.2
Parish, S.3
Sleight, P.4
Peto, R.5
-
7
-
-
0034003042
-
Nitric oxide and vascular responses in Type I diabetes
-
Chan NN, Vallance P, Colhoun HM: Nitric oxide and vascular responses in Type I diabetes. Diabetologia, 2000; 43: 137-147
-
(2000)
Diabetologia
, vol.43
, pp. 137-147
-
-
Chan, N.N.1
Vallance, P.2
Colhoun, H.M.3
-
8
-
-
0242322346
-
Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia
-
Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation, 1998; 98: 1842-1847
-
(1998)
Circulation
, vol.98
, pp. 1842-1847
-
-
Böger, R.H.1
Bode-Böger, S.M.2
Szuba, A.3
Tsao, P.S.4
Chan, J.R.5
Tangphao, O.6
Blaschke, T.F.7
Cooke, J.P.8
-
9
-
-
0035936390
-
Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine
-
Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet, 2001; 358: 2127-2128
-
(2001)
Lancet
, vol.358
, pp. 2127-2128
-
-
Valkonen, V.P.1
Päivä, H.2
Salonen, J.T.3
Lakka, T.A.4
Lehtimäki, T.5
Laakso, J.6
Laaksonen, R.7
-
10
-
-
77951167363
-
Effect of uric acid on coronary microvascular endothelial function in women: Association with eGFR and ADMA
-
Kuwahata S, Hamasaki S, Ishida S, Kataoka T, Yoshikawa A, Orihara K, Ogawa M, Oketani N, Saihara K, Okui H, Shinsato T, Kubozono T, Ichiki H, Fujita S, Takumi T, Yoshino S, Nakazaki M, Miyata M, Tei C: Effect of uric acid on coronary microvascular endothelial function in women: Association with eGFR and ADMA. J Atheroscler Thromb, 2010; 17: 259-269
-
(2010)
J Atheroscler Thromb
, vol.17
, pp. 259-269
-
-
Kuwahata, S.1
Hamasaki, S.2
Ishida, S.3
Kataoka, T.4
Yoshikawa, A.5
Orihara, K.6
Ogawa, M.7
Oketani, N.8
Saihara, K.9
Okui, H.10
Shinsato, T.11
Kubozono, T.12
Ichiki, H.13
Fujita, S.14
Takumi, T.15
Yoshino, S.16
Nakazaki, M.17
Miyata, M.18
Tei, C.19
-
11
-
-
0033537633
-
Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis
-
Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation, 1999; 99: 1141-1146
-
(1999)
Circulation
, vol.99
, pp. 1141-1146
-
-
Miyazaki, H.1
Matsuoka, H.2
Cooke, J.P.3
Usui, M.4
Ueda, S.5
Okuda, S.6
Imaizumi, T.7
-
12
-
-
0035936406
-
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study
-
Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet, 2001; 358: 2113-2117
-
(2001)
Lancet
, vol.358
, pp. 2113-2117
-
-
Zoccali, C.1
Bode-Böger, S.2
Mallamaci, F.3
Benedetto, F.4
Tripepi, G.5
Malatino, L.6
Cataliotti, A.7
Bellanuova, I.8
Fermo, I.9
Frölich, J.10
Böger, R.11
-
13
-
-
33644559016
-
Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population
-
Wanby P, Teerlink T, Brudin L, Brattström L, Nilsson I, Palmqvist P, Carlsson M: Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis, 2006; 185: 271-277
-
(2006)
Atherosclerosis
, vol.185
, pp. 271-277
-
-
Wanby, P.1
Teerlink, T.2
Brudin, L.3
Brattström, L.4
Nilsson, I.5
Palmqvist, P.6
Carlsson, M.7
-
14
-
-
75049084273
-
Asymmetric dimethylarginine (ADMA) as a possible risk marker for ischemic stroke
-
Nishiyama Y, Ueda M, Katsura KI, Otsuka T, Abe A, Nagayama H, Katayama Y: Asymmetric dimethylarginine (ADMA) as a possible risk marker for ischemic stroke. J Neurol Sci, 2010; 290: 12-15
-
(2010)
J Neurol Sci
, vol.290
, pp. 12-15
-
-
Nishiyama, Y.1
Ueda, M.2
Katsura, K.I.3
Otsuka, T.4
Abe, A.5
Nagayama, H.6
Katayama, Y.7
-
15
-
-
3142606890
-
Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia
-
Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM: Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol, 2004; 94: 157-161
-
(2004)
Am J Cardiol
, vol.94
, pp. 157-161
-
-
Lu, T.M.1
Ding, Y.A.2
Leu, H.B.3
Yin, W.H.4
Sheu, W.H.5
Chu, K.M.6
-
16
-
-
1242296340
-
Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?
-
Valkonen VP, Laakso J, Päivä H, Lehtimäki T, Lakka TA, Isomustajärvi M, Ruokonen I, Salonen JT, Laaksonen R: Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler Suppl, 2003; 4: 19-22
-
(2003)
Atheroscler Suppl
, vol.4
, pp. 19-22
-
-
Valkonen, V.P.1
Laakso, J.2
Päivä, H.3
Lehtimäki, T.4
Lakka, T.A.5
Isomustajärvi, M.6
Ruokonen, I.7
Salonen, J.T.8
Laaksonen, R.9
-
17
-
-
34548530600
-
Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats
-
Tanaka N, Katayama Y, Katsumata T, Otori T, Nishiyama Y: Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. Brain Res, 2007; 1169: 125-132
-
(2007)
Brain Res
, vol.1169
, pp. 125-132
-
-
Tanaka, N.1
Katayama, Y.2
Katsumata, T.3
Otori, T.4
Nishiyama, Y.5
-
18
-
-
65549111017
-
Revised equations for estimated GFR from serum creatinine in Japan
-
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 2009; 53: 982-992
-
(2009)
Am J Kidney Dis
, vol.53
, pp. 982-992
-
-
Matsuo, S.1
Imai, E.2
Horio, M.3
Yasuda, Y.4
Tomita, K.5
Nitta, K.6
Yamagata, K.7
Tomino, Y.8
Yokoyama, H.9
Hishida, A.10
-
19
-
-
0031019697
-
Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension
-
Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension, 1997; 29: 242-247
-
(1997)
Hypertension
, vol.29
, pp. 242-247
-
-
Matsuoka, H.1
Itoh, S.2
Kimoto, M.3
Kohno, K.4
Tamai, O.5
Wada, Y.6
Yasukawa, H.7
Iwami, G.8
Okuda, S.9
Imaizumi, T.10
-
20
-
-
0033984125
-
The evolving role of statins in the management of atherosclerosis
-
Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol, 2000; 35: 1-10
-
(2000)
J Am Coll Cardiol
, vol.35
, pp. 1-10
-
-
Vaughan, C.J.1
Gotto Jr., A.M.2
Basson, C.T.3
-
21
-
-
0034037024
-
Impaired endothelial function in arterial hypertension and hypercholesterolemia: Potential mechanisms and differences
-
John S, Schmieder RE: Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens, 2000; 18: 363-374
-
(2000)
J Hypertens
, vol.18
, pp. 363-374
-
-
John, S.1
Schmieder, R.E.2
-
22
-
-
0038796967
-
Heads and hearts. The endothelial connection
-
Vogel RA: Heads and hearts. The endothelial connection. Circulation, 2003; 107: 2766-2768
-
(2003)
Circulation
, vol.107
, pp. 2766-2768
-
-
Vogel, R.A.1
-
23
-
-
0034698038
-
LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine- dependent methyltransferases
-
Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Böger SM: LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine- dependent methyltransferases. Circ Res, 2000; 87: 99-105
-
(2000)
Circ Res
, vol.87
, pp. 99-105
-
-
Böger, R.H.1
Sydow, K.2
Borlak, J.3
Thum, T.4
Lenzen, H.5
Schubert, B.6
Tsikas, D.7
Bode-Böger, S.M.8
-
24
-
-
0242640310
-
Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease
-
Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Flölich JC: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation, 1997; 95: 2068-2074
-
(1997)
Circulation
, vol.95
, pp. 2068-2074
-
-
Böger, R.H.1
Bode-Böger, S.M.2
Thiele, W.3
Junker, W.4
Alexander, K.5
Flölich, J.C.6
-
25
-
-
0035889591
-
Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus
-
Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol, 2001; 88: 1201-1203
-
(2001)
Am J Cardiol
, vol.88
, pp. 1201-1203
-
-
Abbasi, F.1
Asagmi, T.2
Cooke, J.P.3
Lamendola, C.4
McLaughlin, T.5
Reaven, G.M.6
Stuehlinger, M.7
Tsao, P.S.8
-
26
-
-
0032912757
-
Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension
-
Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol, 1999; 33: 652-658
-
(1999)
J Cardiovasc Pharmacol
, vol.33
, pp. 652-658
-
-
Surdacki, A.1
Nowicki, M.2
Sandmann, J.3
Tsikas, D.4
Boeger, R.H.5
Bode-Boeger, S.M.6
Kruszelnicka-Kwiatkowska, O.7
Kokot, F.8
Dubiel, J.S.9
Froelich, J.C.10
-
27
-
-
0034813226
-
Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke
-
Yoo JH, Lee SC: Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis, 2001; 158: 425-430
-
(2001)
Atherosclerosis
, vol.158
, pp. 425-430
-
-
Yoo, J.H.1
Lee, S.C.2
-
28
-
-
0036900697
-
Statins and stroke: Evidence for cholesterol-independent effects
-
Di Napoli P, Taccardi AA, Oliver M, De Caterina R: Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J, 2002; 23: 1908-1921
-
(2002)
Eur Heart J
, vol.23
, pp. 1908-1921
-
-
di Napoli, P.1
Taccardi, A.A.2
Oliver, M.3
de Caterina, R.4
-
29
-
-
0032555154
-
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
-
Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA, 1998; 95: 8880-8885
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 8880-8885
-
-
Endres, M.1
Laufs, U.2
Huang, Z.3
Nakamura, T.4
Huang, P.5
Moskowitz, M.A.6
Liao, J.K.7
-
30
-
-
0033800718
-
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice
-
Laufs U, Gertz K, Huang P, Nickenig G, Böhm M, Dirnagl U, Endres M: Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke, 2000; 31: 2442-2449.
-
(2000)
Stroke
, vol.31
, pp. 2442-2449
-
-
Laufs, U.1
Gertz, K.2
Huang, P.3
Nickenig, G.4
Böhm, M.5
Dirnagl, U.6
Endres, M.7
|